GRM5 and Alzheimer disease: Most importantly, mGluR5 signaling is involved in Abetao‐dependent synaptotoxicity in preclinical models of Alzheimer's disease, and genetic deletion of mGluR5 or negative allosteric modulation was found to reduce plaque pathology and synaptic loss, and to improve cognitive performance.